{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:26:24Z","timestamp":1791296784971,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T00:00:00Z","timestamp":1432080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["FT0991213"],"award-info":[{"award-number":["FT0991213"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Australian National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1074016"],"award-info":[{"award-number":["APP1074016"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Australian National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1093378"],"award-info":[{"award-number":["APP1093378"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Australian National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1025581"],"award-info":[{"award-number":["APP1025581"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Australian National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1027369"],"award-info":[{"award-number":["APP1027369"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ijpddr.2015.05.004","type":"journal-article","created":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T05:22:26Z","timestamp":1434777746000},"page":"117-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites"],"prefix":"10.1016","volume":"5","author":[{"given":"Jessica A.","family":"Engel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky M.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subathdrage D.M.","family":"Sumanadasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-7722","authenticated-orcid":false,"given":"Susanna S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Fairlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina S.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine T.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2015.05.004_bib1","first-page":"452934","article-title":"Lysine acetylation: elucidating the components of an emerging global signaling pathway in trypanosomes","volume":"2012","author":"Alonso","year":"2012","journal-title":"J.\u00a0Biomed. Biotechnol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2958.2004.04151.x","article-title":"Trypanosomatid histones","volume":"53","author":"Alsford","year":"2004","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int. J. Parasitol.-Drugs Drug Resist."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/icb.2011.97","article-title":"HDAC inhibitors in parasitic diseases","volume":"90","author":"Andrews","year":"2012","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib5","first-page":"3467","article-title":"Towards histone deacetylase inhibitors as new antimalarial drugs","volume":"18","author":"Andrews","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib6","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1128\/AAC.00757-07","article-title":"Potent antimalarial activity of histone deacetylase inhibitor analogues","volume":"52","author":"Andrews","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib7","doi-asserted-by":"crossref","first-page":"D539","DOI":"10.1093\/nar\/gkn814","article-title":"PlasmoDB: a functional genomic database for malaria parasites","volume":"37","author":"Aurrecoechea","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.exppara.2008.11.010","article-title":"Schistosoma mansoni: developmental arrest of miracidia treated with histone deacetylase inhibitors","volume":"121","author":"Azzi","year":"2009","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib9","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/emboj\/19.11.2435","article-title":"RAP1 controls rhoptry targeting of RAP2 in the malaria parasite Plasmodium falciparum","volume":"19","author":"Baldi","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","article-title":"A\u00a0phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1517\/17460441.3.2.173","article-title":"Recent initiatives and strategies to developing new drugs for tropical parasitic diseases","volume":"3","author":"Caffrey","year":"2008","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1358\/dot.2009.45.11.1437052","article-title":"Romidepsin for the treatment of cutaneous T-cell lymphoma","volume":"45","author":"Campas-Moya","year":"2009","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2014.12.066","article-title":"Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT)","author":"Carrillo","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chom.2014.06.014","article-title":"A\u00a0Plasmodium falciparum histone deacetylase regulates antigenic variation and gametocyte conversion","volume":"16","author":"Coleman","year":"2014","journal-title":"Cell. Host Microbe"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib16","doi-asserted-by":"crossref","first-page":"13143","DOI":"10.1073\/pnas.93.23.13143","article-title":"Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase","volume":"93","author":"Darkin-Rattray","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"De Ruijter","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib18","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1128\/AAC.00439-08","article-title":"Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors","volume":"52","author":"Dow","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molbiopara.2009.06.001","article-title":"Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni","volume":"168","author":"Dubois","year":"2009","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/1087057114556236","article-title":"Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei","volume":"20","author":"Faria","year":"2015","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cell.2005.01.037","article-title":"Telomeric heterochromatin propagation and histone acetylation control mutually exclusive expression of antigenic variation genes in malaria parasites","volume":"121","author":"Freitas-Junior","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib22","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib24","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","article-title":"A\u00a0phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies","volume":"12","author":"Giles","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2227","article-title":"Vorinostat","volume":"6","author":"Grant","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cmdc.201300469","article-title":"Synthesis, antimalarial properties, and SAR studies of alkoxyurea-based HDAC inhibitors","volume":"9","author":"Hansen","year":"2014","journal-title":"ChemMedChem."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejmech.2014.05.050","article-title":"Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages","volume":"82","author":"Hansen","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2958.2002.03018.x","article-title":"Histone deacetylases in Trypanosoma brucei: two are essential and another is required for normal cell cycle progression","volume":"45","author":"Ingram","year":"2002","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/17460441.2013.783816","article-title":"Whole-organism high-throughput screening against Trypanosoma brucei brucei","volume":"8","author":"Jones","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib30","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.bmcl.2012.01.072","article-title":"Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei","volume":"22","author":"Kelly","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Khan","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/icb.2011.100","article-title":"HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications","volume":"90","author":"Khan","year":"2012","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib33","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1128\/AAC.48.4.1435-1436.2004","article-title":"Antimalarial and antileishmanial activities of aroyl-pyrrolyl-hydroxyamides, a new class of histone deacetylase inhibitors","volume":"48","author":"Mai","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib34","doi-asserted-by":"crossref","first-page":"16708","DOI":"10.1073\/pnas.1205414109","article-title":"Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum","volume":"109","author":"Malmquist","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.molbiopara.2007.07.005","article-title":"Histone modifications in Trypanosoma brucei","volume":"156","author":"Mandava","year":"2007","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/epi.3.1.5736","article-title":"HDACs and HDAC inhibitors in colon cancer","volume":"3","author":"Mariadason","year":"2008","journal-title":"Epigenetics"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.gene.2005.10.022","article-title":"The malaria parasite Plasmodium falciparum histones: organization, expression, and acetylation","volume":"369","author":"Miao","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"A\u00a0phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study","volume":"109","author":"Modesitt","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mdp270","article-title":"Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)","volume":"21","author":"Molife","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0960-894X(01)00049-X","article-title":"The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin","volume":"11","author":"Murray","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib41","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nrd2144","article-title":"Innovative lead discovery strategies for tropical diseases","volume":"5","author":"Nwaka","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib42","first-page":"473","article-title":"A\u00a0new fluorometric assay for cytotoxicity measurements in-vitro","volume":"3","author":"Page","year":"1993","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib43","doi-asserted-by":"crossref","first-page":"37964","DOI":"10.1074\/jbc.M110.155317","article-title":"Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug","volume":"285","author":"Pallavi","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jinorgbio.2013.03.011","article-title":"A\u00a0novel platinum complex of the histone deacetylase inhibitor belinostat: rational design, development and in\u00a0vitro cytotoxicity","volume":"124","author":"Parker","year":"2013","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib45","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1021\/jm801654y","article-title":"Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum","volume":"52","author":"Patel","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bmc.2009.10.042","article-title":"Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group","volume":"18","author":"Patil","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/fon.09.36","article-title":"Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors","volume":"5","author":"Prince","year":"2009","journal-title":"Future Oncol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib48","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-11-3144","article-title":"Romidepsin for cutaneous T-cell lymphoma","volume":"18","author":"Prince","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-010-1289-x","article-title":"A\u00a0phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer","volume":"66","author":"Rathkopf","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib50","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1158\/1078-0432.CCR-06-1802","article-title":"A\u00a0study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer","volume":"12","author":"Rubin","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib51","first-page":"718","article-title":"Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms","volume":"8","author":"Sandor","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib52","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1074\/jbc.M312307200","article-title":"Bloodstream form-specific up-regulation of silent vsg expression sites and procyclin in Trypanosoma brucei after inhibition of DNA synthesis or DNA damage","volume":"279","author":"Sheader","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib53","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib54","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00280-010-1419-5","article-title":"Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)","volume":"67","author":"Steele","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"20","key":"10.1016\/j.ijpddr.2015.05.004_bib69","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1016\/j.jmb.2014.03.007","article-title":"Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen schistosoma mansoni","volume":"426","author":"Stolfa","year":"2014","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib56","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1128\/AAC.00030-12","article-title":"Antimalarial activity of the anticancer histone deacetylase inhibitor SB939","volume":"56","author":"Sumanadasa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib57","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1038\/srep03743","article-title":"Chemical signatures and new drug targets for gametocytocidal drug development","volume":"4","author":"Sun","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib58","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/cmdc.201402098","article-title":"Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds","volume":"9","author":"Sundriyal","year":"2014","journal-title":"ChemMedChem."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib59","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4269\/ajtmh.2009.09-0015","article-title":"Development of an Alamar blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427","volume":"81","author":"Sykes","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib60","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.2146\/news140056","article-title":"Belinostat approved for use in treating rare lymphoma","volume":"71","author":"Thompson","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib61","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1371\/journal.pbio.1000084","article-title":"Sir2 paralogues cooperate to regulate virulence genes and antigenic variation in Plasmodium falciparum","volume":"7","author":"Tonkin","year":"2009","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib62","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1128\/AAC.02721-13","article-title":"Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules","volume":"58","author":"Trenholme","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib63","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1126\/science.3299700","article-title":"Genetic analysis of the human malaria parasite Plasmodium falciparum","volume":"236","author":"Walliker","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib64","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1365-2958.2010.07284.x","article-title":"Histone deacetylases play distinct roles in telomeric VSG expression site silencing in African trypanosomes","volume":"77","author":"Wang","year":"2010","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib65","first-page":"813","article-title":"Chromosome size variation occurs in cloned Plasmodium falciparum on in\u00a0vitro cultivation","volume":"11","author":"Wellems","year":"1988","journal-title":"Rev. Bras. Genet."},{"key":"10.1016\/j.ijpddr.2015.05.004_bib66","series-title":"Global Burden of Disease: 2004 Update","author":"WHO","year":"2008"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib67","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ijpddr.2015.05.004_bib68","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2011.41.2395","volume":"30","author":"Yeo","year":"2012","journal-title":"J.\u00a0Clin. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.ijpddr.2016.05.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000}}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320715000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320715000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T12:23:19Z","timestamp":1537532599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320715000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S2211320715000123"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2015.05.004","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ijpddr.2016.05.001","asserted-by":"object"}]},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2015.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}